The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 07, 2017

Filed:

Jun. 20, 2014
Applicants:

Medimmune, Llc, Gaithersburg, MD (US);

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

William Dall'Acqua, Gaithersburg, MD (US);

Leslie S. Johnson, Darnestown, MD (US);

Elizabeth Sally Ward Ober, Dallas, TX (US);

Assignees:

MedImmune LLC, Gaithersburg, MD (US);

Board of Regents, The University of Texas System, Austin, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/00 (2006.01); C12P 21/08 (2006.01); C07K 16/28 (2006.01); A61K 47/48 (2006.01); A61K 49/00 (2006.01); C07K 14/705 (2006.01); C07K 2/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/283 (2013.01); A61K 47/48507 (2013.01); A61K 49/0002 (2013.01); A61K 49/0004 (2013.01); C07K 2/00 (2013.01); C07K 14/70503 (2013.01); C07K 16/00 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); Y10S 435/81 (2013.01);
Abstract

The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.


Find Patent Forward Citations

Loading…